�
28 July 2017 11:00 BST
�
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
�
AstraZeneca PLC (the Company) announces that, on 27 July 2017, it was notified by Nazneen Rahman, a Non-Executive Director of the Company, that, on 27 July 2017, Professor Rahman purchased 500 Ordinary Shares of $0.25 each in the Company (Shares) at an aggregate price of 4338.186 pence per Share.
�
The Company also announces that, on 27 July 2017, it was notified by Philip Broadley, a Non-Executive Director of the Company, that, on 27 July 2017, Mr Broadley purchased 2,300 Shares at a price of 4282 pence per Share.
�
The attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail.
�
|
1 � |
Details of the person discharging managerial responsibilities / person closely associated � |
|||||||
|
a) � |
Name � � |
Nazneen Rahman |
||||||
|
2 � |
Reason for the notification � |
|||||||
|
a) � |
Position/status � � |
Non-Executive Director |
||||||
|
b) � |
Initial notification /Amendment � � |
Initial notification |
||||||
|
3 � |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor � |
|||||||
|
a) � |
Name � � |
AstraZeneca PLC |
||||||
|
b) � |
LEI � � |
PY6ZZQWO2IZFZC3IOL08 |
||||||
|
4 � |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted � � |
|||||||
|
a) � |
Description of the financial instrument, type of instrument � Identification code � � |
Ordinary Shares of US$0.25 each in AstraZeneca PLC � � GB0009895292 � |
||||||
|
b) � |
Nature of the transaction � � |
Share purchase |
||||||
|
c) � |
Price(s) and volume(s) � � |
�
|
||||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
500
4338.1860 pence
|
||||||
|
e)
|
Date of the transaction
|
27 July 2017 |
||||||
|
f)
|
Place of the transaction
|
XLON |
||||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Philip Broadley |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Director |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
AstraZeneca PLC |
||||
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
||||
|
b)
|
Nature of the transaction
|
Share purchase |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
27 July 2017 |
||||
|
f)
|
Place of the transaction
|
XLON |
||||
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & M etabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
|
Media Relations |
|
|
|
Esra Erkal-Paler |
UK/Global |
+44 203 749 5638 |
|
Rob Skelding |
UK/Global |
+44 203 749 5821 |
|
Karen Birmingham |
UK/Global |
+44 203 749 5634 |
|
Matt Kent |
UK/Global |
+44 203 749 5906 |
|
Jacob Lund |
Sweden |
+46 8 553 260 20 |
|
Michele Meixell |
US |
+1 302 885 2677 |
|
|
|
|
|
Investor Relations |
|
|
|
Thomas Kudsk Larsen |
|
+44 203 749 5712 |
|
Craig Marks |
Finance, Fixed Income, M&A |
+44 7881 615 764 |
|
Henry Wheeler |
Oncology |
+44 203 749 5797 |
|
Mitchell Chan |
Oncology |
+1 240 477 3771 |
|
Lindsey Trickett |
Cardiovascular & Metabolic Diseases (CVMD) |
+1 240 543 7970 |
|
Nick Stone |
Respiratory |
+44 203 749 5716 |
|
Christer Gruvris |
Autoimmunity, Neuroscience & Infection |
+44 203 749 5711 |
|
US toll free |
|
+1 866 381 7277 |
Adrian Kemp
Company Secretary
AstraZeneca PLC